La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Alvotech a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Alvotech..

Alvotech (NASDAQ:ALVO) Azioni, Catena delle Opzioni

Alvotech

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.

ALVOPETRO ENEGY LTD by Alvopetro Energy Ltd

Alvopetro Energy Ltd

ALVO MINERALS LTD by ALVO MINERALS LTD.

News

Reported Saturday, CSX Secures Labor Agreement With BMWED, Covering 42% Of Unionized Workforce

<ul>
<li>-- Strategic Partnership Strengthens Gilead's Inflammation Research Portfolio with the Addition of LEO Pharma's Preclinical Oral STAT6 Program, Including Targeted Protein Degraders --</li>
<li>-- Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S. --</li>
<li>-- LEO Pharma to Maintain Global Rights to Topical Formulations of the STAT6 Program in Dermatology --</li>
</ul>

GILD

Reported Saturday, Gilead And LEO Pharma Join Forces To Accelerate Oral STAT6 Development For Inflammation And Dermatology

<ul>
<li>Blue Owl to place logo patches on dozens of athletes competing across the Australian Open, French Open, Wimbledon, and US Open</li>
<li>Jordan Thompson named as Blue Owl's dedicated athlete ambassador for the Australian Open</li>
</ul>

Reported Sunday, Blue Owl Capital Expands Grand Slam Sponsorship, Partners With Jordan Thompson For Australian Open 2025

Dearborn-based Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) sold 51,745 Mustang Mach-E <a href="https://www.benzinga.com/25/01/42801670/mustang-mach-e-spurs-fords-ev-sales-in-q4-after-it-delays-new-vehicle-launch">SUVs in the U.S. </a>last year, trumping the sales numbers of its gas-powered counterpart Mustang for the first time since the EV&#8217;s sales commenced in late 2020.
What Happened: In the last quarter of 2020, Ford sold three units of the electric Mach-E and officially commenced the sales of the EV. In the whole year, the company had sold 61,090 units of the Mustang. 
In every year since Mach-E sales rose while Mustang sales dipped until last year when Mach-E sales trumped the sales of its gas counterpart under the same nameplate. 
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Year</td>
<td>Mustang Mach-E Sales</td>
<td>Mustang Sales</td>
</tr>
<tr>
<td>2020</td>
<td>3</td>
<td>61,090</td>
</tr>
<tr>
<td>2021</td>
<td>27,140</td>
<td>52,414</td>
</tr>
<tr>
<td>2022</td>
<td>39,458</td>
<td>47,566</td>
</tr>
<tr>
<td>2023</td>
<td>40,771</td>
<td>48,605</td>
</tr>
<tr>
<td>2024</td>
<td>51,745</td>
<td>44,003</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Ford</figcaption></figure>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="370" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13032212/hOMJj-ford-mustang-mach-e-sales-since-2020-1024x370.png" alt="" class="wp-image-729887" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13032212/hOMJj-ford-mustang-mach-e-sales-since-2020-1024x370.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13032212/hOMJj-ford-mustang-mach-e-sales-since-2020-300x108.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13032212/hOMJj-ford-mustang-mach-e-sales-since-2020-768x277.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/13032212/hOMJj-ford-mustang-mach-e-sales-since-2020.png 1240w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Why It Matters: Ford&#8217;s Mach-E is one of Ford&#8217;s three EVs sold in the U.S. besides the F-150 Lightning pickup truck and the E-transit electric van. 
Last year, Ford sold 97,865 electric vehicles, accounting for merely 4.7% of its overall vehicle sales in the year. 
A majority of Ford&#8217;s sales include combustion engine vehicles and the company has a long <a href="https://www.benzinga.com/news/24/04/38285214/fords-mustang-gallops-into-60th-year-still-a-pony-with-plenty-of-kick">lineup of gas-powered vehicles</a> besides its best-selling F-series truck or its Explorer SUV.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42937389/tesla-hikes-model-3-y-prices-in-canada-by-c1000-after-announcing-price-increase-in-china">Tesla Hikes Model 3, Y Prices In Canada By C$1000 After Announcing Price Increase In China</a></li>
</ul>
Photo courtesy: Ford

Tech

Ford Sold More Electric Mustangs Than Gas Mustangs In 2024

JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) CEO Jamie Dimon offered praise for Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) CEO Elon Musk while sharing insights on American political dynamics in an interview.
What Happened: &#8220;He&#8217;s clearly an extraordinary talent,&#8221; Dimon said of Musk, citing achievements at Tesla and SpaceX. The banking executive dismissed concerns on CBS&#8217;s 60 Minutes <a href="https://www.youtube.com/watch?v=2REdbQasKX4">interview</a> about Musk&#8217;s influence on right-wing European politics, comparing it to historical precedents like Charles Lindbergh, an American aviator, military officer, and author&#8217;s political involvement.
&#8220;I mean, to look at Tesla and SpaceX — and his attitude is, &#8220;Yeah, well, we should make government more efficient.&#8221; Is this the way to do it? I don't know. Do I want him to succeed? Absolutely,&#8221; Dimon said.
Dimon, who heads America&#8217;s largest bank, expressed &#8220;cautious pessimism&#8221; about the economy despite positive indicators including lower unemployment and cooling inflation. 
When asked if he was surprised by President-elect Donald Trump&#8216;s 2024 election victory, Dimon responded with a simple &#8220;no.&#8221; He attributed Trump's success to widespread public frustration with government inefficiency and the perceived condescension in social policy approaches.
&#8220;People were angry at what they call the &#8216;state,&#8217; you know, the swamp, ineffective government,&#8221; Dimon told interviewer Lesley Stahl. &#8220;They didn&#8217;t want to be lectured to on social policies continuously.&#8221;
See Also: <a href="https://www.benzinga.com/personal-finance/25/01/42932900/elon-musks-ex-wife-and-mother-to-his-5-kids-says-his-secret-to-extreme-success-is-working-harder-than-average-bear-and-saying-no-a-lot">Elon Musk&#8217;s Ex-Wife And Mother To His 5 Kids Says His Secret To Extreme Success Is Working Harder Than &#8216;Average Bear&#8217; And Saying &#8216;No&#8217; A Lot</a>
Why It Matters: The comments come after previous speculation about Dimon&#8217;s potential role in the Trump administration. JPMorgan in October clarified that Dimon &#8220;has not endorsed anyone&#8221; after Trump <a href="https://www.benzinga.com/general/politics/24/10/41192406/jamie-dimon-rejects-trump-endorsement-claim-casting-doubt-on-treasury-rumors">claimed otherwise on Truth Social</a>. 
The denial casts doubt on earlier reports that Trump was considering Dimon for Treasury Secretary, especially given Trump&#8217;s historical preference for political loyalists in cabinet positions.
During his tenure at JPMorgan, Dimon has maintained a pragmatic stance on political matters while focusing on economic issues and banking sector stability. Under his leadership, JPMorgan Chase has grown to become the largest U.S. bank by assets, with significant influence in global financial markets.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/personal-finance/25/01/42898261/bill-and-melinda-gates-say-they-raised-their-3-daughters-with-a-middle-class-upbringing-youre-not-allowed-to-tell-people-how-we-flew">Bill And Melinda Gates Say They Raised Their 3 Daughters With A &#8216;Middle-Class&#8217; Upbringing–&#8217;You&#8217;re Not Allowed to Tell People How We Flew …&#8217;</a></li>
</ul>
Image Via Flickr 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Equities

Markets

TSLA

Jamie Dimon Calls Elon Musk 'An Extraordinary Talent' — JP Morgan CEO Shares Why Trump's Election Victory Didn't Surprise Him

Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025
Alvelestat, for Alpha-1 Antitrypsin Deficiency-associated Lung Disease, receives positive EMA opinion on European Orphan Designation Application; European Commission expected to issue final decision in first quarter 2025

MREO

Reported Sunday, Mereo BioPharma Reports Progress In Setrusumab Phase 3 Study For OI And Awaits EMA Decision On Alvelestat Orphan Designation

FY 2024 revenue of ~$611 million and Q4 2024 revenue of ~$165 million, representing 9% growth sequentially

Reported Sunday, 10x Genomics Reports $610.8M In 2024 Revenue (-1% YoY), $165M Q4 Revenue (-10% YoY), And $393M In Cash Reserves

Tesla Inc. CEO Elon Musk endorsed calls for Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) to release its content moderation communications with government officials, responding &#8220;That would be good&#8221; to prominent tech investor Dave Lee&#8216;s demand for transparency.
What Happened: &#8220;If Zuck is serious then let&#8217;s see the <a href="https://www.benzinga.com/government/22/12/30119008/elon-musks-twitter-files-part-6-drops-company-acted-as-fbis-subsidiary-a-one-big-happy-family-vibe">equivalent of the Twitter Files</a> for Facebook. Show all the communication back and forth (not just handpicked ones) between the government and Facebook regarding COVID/vaccine censorship,&#8221; Lee wrote on X, drawing Musk&#8217;s support.
The Twitter Files were a <a href="https://www.benzinga.com/news/22/12/29949435/twitter-files-revealed-musk-reacts-to-exposure-of-company-response-to-hunter-biden-story">series of internal Twitter documents </a>that were released in 2022–2023 by journalists and authors.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">That would be good <a href="https://t.co/Fkmj5ctjr5">https://t.co/Fkmj5ctjr5</a>
&mdash; Elon Musk (@elonmusk) <a href="https://twitter.com/elonmusk/status/1878693613313663295?ref_src=twsrc%5Etfw">January 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
The exchange comes as Meta CEO Mark Zuckerberg announced plans to adopt a feature similar to X&#8217;s Community Notes, signaling a major shift in <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">content moderation strategy</a>. During a video announcement, Zuckerberg acknowledged past censorship mistakes and outlined plans to &#8220;get back to our roots around free expression on Facebook and Instagram.&#8221;
Meta&#8217;s internal data reveals the scope of <a href="https://www.benzinga.com/tech/25/01/42779753/mark-zuckerbergs-meta-replaces-global-affairs-chief-nick-clegg-with-republican-joel-kaplan-ahead-of-trump-inauguration">current moderation practices</a>, with Joel Kaplan, the company&#8217;s new head of global affairs, disclosing that 10-20% of December&#8217;s content removals may have been erroneous. The platform&#8217;s pivot includes phasing out third-party fact-checkers and relocating trust and safety teams <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">from California to Texas</a>.
See Also: <a href="https://www.benzinga.com/markets/equities/25/01/42938119/lockheed-martin-donates-1m-to-trumps-inaugural-committee-as-speculation-grows-over-elon-musk-led-doge-crackdown-on-traditional-defense-contracts">Lockheed Martin Donates $1M To Trump&#8217;s Inaugural Committee As Speculation Grows Over Elon Musk-Led DOGE Crackdown On Traditional Defense Contracts</a>
Why It Matters: The changes follow Zuckerberg&#8217;s recent $1 million donation to President-elect Donald Trump&#8216;s inauguration fund and their November meeting at Mar-a-Lago. During a Joe Rogan podcast appearance, Zuckerberg detailed past tensions with President Joe Biden&#8216;s administration officials, describing instances where they &#8220;would call up our team and, like, scream at them and curse&#8221; over <a href="https://www.benzinga.com/25/01/42931361/mark-zuckerberg-says-biden-officials-berated-meta-staff-as-they-refused-to-remove-true-content-it-just-got-to-this-pointthats-ridiculous">content removal requests</a>.
X CEO Linda Yaccarino praised Meta&#8217;s decision, calling it a &#8220;smart move by Zuck&#8221; and suggesting other <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">platforms would follow</a>. 
The platform&#8217;s transformation includes adding three <a href="https://www.benzinga.com/25/01/42851889/meta-ditches-fact-checking-for-community-notes-zuckerberg-says-opportunity-to-restore-free-expression">new board members</a>, including Trump ally Dana White, indicating strategic alignment with the incoming administration and a marked departure from its previous content moderation approach during the COVID-19 pandemic and 2020 election cycle.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/global/25/01/42938329/us-reportedly-probes-barriers-subsidies-and-unfair-trade-practices-by-china-in-global-shipbuilding-as-trump-tariff-threat-looms">US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms</a></li>
</ul>
Image Via Shutterstock 
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Social Media

Elon Musk Urges Mark Zuckerberg To Release Facebook Files, Calls It 'Good' After Meta Adopts X's Community Notes-Like Feature

<ul>
<li>New biomarkers on track for commercial launch in January 2025</li>
<li>Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn</li>
</ul>

Reported Earlier, Exagen Expects $55.3M-$55.8M In Annual Revenue (+33% YoY), And Narrowed EBITDA Loss Of $9.8M–$10.8M In 2024; For Q4 Sees $13.3M-$13.8M In Revenue

<ul>
<li>Revenue of $1,021.8 Million Grows 0.9% --</li>
<li>-- Revenue Increases 1.0% on Constant Currency Basis, In-Line with Guidance –</li>
<li>– GAAP and Non-GAAP EPS Expected to be Near High End of Guidance Ranges –</li>
</ul>

HOLX

Reported Earlies, Hologic Reports Preliminary Q1 FY25 Revenue Of $1.02B (+0.9% YoY), EPS Expected Near High-End Of Guidance

With U.S. stock futures trading lower this morning on Monday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Comtech Telecommunications Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) to report a quarterly loss at 16 cents per share on revenue of $125.53 million before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Comtech Telecommunications shares gained 3.9% to $4.29 in after-hours trading.</li>
<li>WD-40 Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDFC#NASDAQ">WDFC</a>) posted better-than-expected results for its first quarter and reiterated its FY25 guidance on Friday. WD-40 shares gained 5.5% to $254.00 in the after-hours trading session.</li>
<li>Analysts are expecting KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) to post quarterly earnings at $2.45 per share on revenue of $1.99 billion. The company will release earnings after the markets close. KB Home shares gained 0.1% to $63.25 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>Nordstrom Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JWN#NYSE">JWN</a>) said total company net sales rose 4.9%, while comparable sales increased 5.8% for the nine-week holiday period ended Jan. 4. The company also said it sees comparable sales growth of 2.5% to 3.5% versus 52 weeks in fiscal 2023, up from its previous guidance of 1.0% to 2.0% growth. Nordstrom shares gained 0.2% to $24.05 in the after-hours trading session.</li>
<li>Analysts expect ServiceTitan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) to post a quarterly loss at 3 cents per share on revenue of $198.52 million after the closing bell. ServiceTitan shares gained 0.1% to $101.40 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42923396/wall-streets-most-accurate-analysts-weigh-in-on-3-real-estate-stocks-with-over-7-dividend-yields-2">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Earnings

Pre-Market Outlook

Trading Ideas

CMTL

TTAN

WDFC

WD-40 Company, KB Home And 3 Stocks To Watch Heading Into Monday

<h3>Companies Reporting Before The Bell</h3>
• Comtech Telecom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMTL#NASDAQ">CMTL</a>) is estimated to report quarterly loss at $0.36 per share on revenue of $125.53 million. 
<h3>Companies Reporting After The Bell</h3>
• Calamos Glb Total (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGO#NASDAQ">CGO</a>) is estimated to report quarterly earnings at $2.88 per share on revenue of $770.40 million. 
• ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) is projected to report earnings for its third quarter. 
• KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) is likely to report quarterly earnings at $2.47 per share on revenue of $1.98 billion. 
• Aehr Test System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEHR#NASDAQ">AEHR</a>) is expected to report quarterly earnings at $0.03 per share on revenue of $15.04 million. 
• Educational Development (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDUC#NASDAQ">EDUC</a>) is expected to report earnings for its third quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AEHR

EDUC

Earnings Scheduled For January 13, 2025

<ul>
<li>– Full Year 2024 Preliminary Net Product Revenues of $1,646 Million for ONPATTRO&#xAE;, AMVUTTRA&#xAE;, GIVLAARI&#xAE;, and OXLUMO&#xAE;, Representing 33% Annual Growth –</li>
<li>– 2025 Combined Net Product Revenue Guidance&#x2A;&#x2A; of $2,050 Million to $2,250 Million Positions Company to Achieve Alnylam P5x25 Goal of Non-GAAP Profitability –</li>
<li>– Robust Clinical Pipeline with Multi-Billion-Dollar Opportunities for Sustainable Growth –</li>
</ul>

ALNY

Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals

<ul>
<li>-- Updating peak systemic&nbsp;mastocytosis franchise revenue opportunity to $4 billion, catalyzed by strong AYVAKIT&#xAE; (avapritinib) launch and evolving SM prevalence estimates --</li>
<li>&nbsp;-- Expect to achieve $2 billion in AYVAKIT revenue by 2030 --</li>
<li>-- BLU-808 demonstrates wide therapeutic window with rapid, robust and sustained&nbsp;tryptase reductions exceeding 80% in Phase 1 healthy volunteer study --</li>
</ul>

BPMC

Reported Earlier, Blueprint Medicines Sees AYVAKIT 2024 Revenue At $475M–$480M (+130% YoY); Projects $4B SM Franchise Opportunity, Targets $2B AYVAKIT Revenue By 2030;

<ul>
<li>– Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product revenues for fiscal year 2024 –</li>
<li>– Fiscal year 2025 net product revenues guidance of $1.95 billion - $2.05 billion –</li>
<li>– Presentation and webcast at 43rd Annual J.P. Morgan Healthcare Conference tomorrow, Monday, January 13th at 5:15 p.m. PT / 8:15 p.m. ET –</li>
</ul>

EXEL

Reported Earlier, Exelixis Reports $2.165B In Preliminary 2024 Revenue, Projects $2.15B-2.25B In 2025, And Highlights Pipeline Progress

Ahead of President Joe Biden&#8216;s departure from office, a U.S. investigation has concluded that China engages in unfair&nbsp;practices to dominate the global&nbsp;shipbuilding industry. 
What Happened: The probe, initiated by&nbsp;U.S. Trade Representative Katherine Tai&nbsp;in April, was requested by the United Steelworkers and other&nbsp;unions under Section 301 of&nbsp;the Trade Act of 1974. This revelation could lead to potential penalties against China, according to&nbsp;Reuters&nbsp;on Monday. 
Investigators found that China uses&nbsp;financial support, barriers for foreign&nbsp;firms, forced technology transfer, and intellectual property theft to gain an advantage in shipbuilding, a source told Reuters. The report also highlights China&#8217;s suppression of labor costs in the maritime and logistics sectors. The findings could lead to&nbsp;tariffs or port fees on&nbsp;Chinese-built vessels.
The report indicates that China&#8217;s share in&nbsp;the $150 billion global shipbuilding&nbsp;market has grown from 5% in 2000&nbsp;to over 50% in 2023, largely due to government subsidies. Meanwhile, U.S. shipbuilders&#8217; market share has fallen below 1%. The U.S. Trade Representative&#8217;s office is expected to release the findings later this week, just before President Biden leaves office on Jan. 20.
This investigation follows previous&nbsp;efforts by the Biden administration&nbsp;to curb China&#8217;s influence through tariffs and export controls. Experts suggest that rebuilding the U.S. shipbuilding industry will require substantial investment and time.
Why It Matters: The U.S. probe into China&#8217;s shipbuilding practices has sparked significant controversy. Last year, the Chinese Ministry of Commerce <a href="https://www.benzinga.com/news/24/04/38312330/mistake-on-top-of-a-mistake-china-slams-us-probe-into-its-maritime-and-shipbuilding-sectors">criticized the investigation</a>, calling it a &#8220;mistake on top of a mistake,&#8221; asserting that China&#8217;s industrial growth is driven by technological innovation and market competition. 
Additionally, China is projected to surpass the <a href="https://www.benzinga.com/news/24/10/41142611/china-set-to-surpass-us-in-advanced-military-manufacturing-by-2035-report">U.S. in advanced technology </a>and military manufacturing by 2035, as reported by the South China Morning Post. Former vice-chairman of the National People&#8217;s Congress, Lu Yongxiang, emphasized that the decline of U.S. manufacturing is irreversible, suggesting a rapidly diminishing competitive edge for the U.S.
Meanwhile, Chinese policymakers are reportedly considering <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42473889/china-eyes-yuan-devaluation-to-counter-trumps-tariffs-will-it-work">allowing yuan devaluation</a> in 2025 to counter the economic impact of Trump&#8217;s proposed potential 60% tariff on Chinese imports.
Read More:
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42931758/apple-staring-at-market-share-decline-in-china-amid-declining-iphone-shipments-top-analyst-flags-why-some-models-could-be-face-shipping-momentum-challenges">Apple Staring At Market Share Decline In China Amid Declining iPhone Shipments: Top Analyst Flags Why Some Models Could Be Face Shipping Momentum Challenges</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Image via Shutterstock

Global

General

US Reportedly Probes Barriers, Subsidies And Unfair Trade Practices By China In Global Shipbuilding As Trump Tariff Threat Looms

<ul>
<li>2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1</li>
<li>Strong and Growing Demand for Galafold&#xAE; and Pombiliti&#xAE; + Opfolda&#xAE;</li>
<li>Total Revenue Growth of 17-24% at CER Expected in 2025</li>
<li>&gt;3,000 People Treated with an Amicus Therapy Today2</li>
</ul>

FOLD

Reported Earlier, Amicus Reported $528M In 2024 Revenue (+32% YoY), Projects 17-24% Growth In 2025, And Highlights First Full Year Of Pombiliti + Opfolda Sales

Financial Update
<ul>
<li>Unaudited preliminary estimate of total full-year 2024 product revenue of ~€226 million:
<ul>
<li>SKYTROFA full-year 2024 revenue expected to be ~€202 million excluding sales deductions related to prior years (based on unaudited preliminary estimate of full-year 2024 SKYTROFA revenue of ~€197 million plus ~€5 million of sales deductions related to prior years).</li>
<li>YORVIPATH full-year 2024 unaudited preliminary revenue estimate of ~€29 million.</li>
</ul>
</li>
<li>Unaudited preliminary estimate of total full-year total 2024 revenue of ~€364 million
<ul>
<li>Includes $100 million Novo Nordisk milestone payment as non-product revenue.</li>
</ul>
</li>
<li>December 31, 2024 pro forma cash balance of ~€655 million (based on unaudited preliminary estimate of December 31, 2024 cash balance of €560 million plus expected payment from Novo Nordisk of $100 million).</li>
</ul>

ASND

Reported Earlier, Ascendis Pharma Projects €364M In 2024 Revenue, Reports €655M In Cash, Highlights SKYTROFA And YORVIPATH Growth, And Prepares For Transcon CNP NDA Filing In Early 2025

Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), a global leader in DNA sequencing and array-based technologies, today announced a pilot proteomics program to analyze 50,000 UK Biobank samples in collaboration with deCODE Genetics, Standard BioTools, Tecan, GSK, Johnson &amp; Johnson, and Novartis. The pilot program is based on Illumina's upcoming proteomics assay, Illumina Protein Prep&#x2122;, powered by SOMAmer&#xAE; technology, a next-generation sequencing (NGS) based solution that will help scale access to proteomic insights.

ILMN

Illumina Launches Proteomics Pilot with 50,000 UK Biobank Samples, Partners with GSK, J&J, and Novartis

Arthur Hayes, co-founder of cryptocurrency exchange&nbsp;BitMEX and Chief Investment Officer at&nbsp;Maelstrom&nbsp;Fund, cast aspersions on MicroStrategy Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) debt-powered Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) buying strategy, forecasting challenging times for the firm when the top cryptocurrency loses volatility.
What happened: In an interview with Benzinga, Hayes slammed MicroStrategy&#8217;s volatility monetization play, which includes issuing convertible debt and other fixed-income securities to buy Bitcoin.
&#8220;The reason why these are attractive instruments is because the stock and the Bitcoin they purchase, are volatile,&#8221; Hayes said. 
Bitcoin has experienced a record-breaking run, rising by almost 50% in the last three months, helped by Donald Trump&#8217;s presidential victory. The rally has caused extreme upside volatility in Michael Saylor&#8217;s MicroStrategy, known more for its Bitcoin portfolio than the core software business. The stock has moved 62% in the last three months.
However, Hayes warned that things may not remain the same. &#8220;When the volatility of Bitcoin declines, most likely after a major crash, it will become difficult for MSTR to attract interest in these types of debt. At that point, the game is up.&#8221;
The Bitcoin bull said he won&#8217;t trade the MSTR stock at all, arguing that there are &#8220;better&#8221; ways to go long or short on Bitcoin.
See Also:<a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading"> </a><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42936962/shytoshi-kusama-outlines-treat-tokens-usefulness-ahead-of-launch-optimistic-whales-buy-up-shiba-inu">Shytoshi Kusama Outlines TREAT Token&#8217;s Usefulness Ahead Of Launch, Optimistic Whales Buy Up Shiba Inu</a>
Why It Matters: Hayes&#8217; remarks added to the growing concerns around MicroStrategy&#8217;s Bitcoin purchases.
Well-known economist Peter Schiff&nbsp;said previously that the company&#8217;s commitment to repay convertible note holders could be at a&nbsp;<a href="https://www.benzinga.com/24/11/42237876/peter-schiff-predicts-microstrategys-bankruptcy-due-to-bitcoin-investment-strategy" target="_blank" rel="noreferrer noopener">potential risk</a>&nbsp;if Bitcoin drops significantly in value.
Martin Shkreli, known popularly as "Pharma Bro," <a href="https://www.benzinga.com/24/12/42735744/pharma-bro-martin-shkreli-predicts-doom-for-michael-saylors-microstrategy-as-stock-dips-below-300-in-after-hours-trading">went to the extent of calling </a>the play a &#8220;big bubble," adding that he was short on MicroStrategy.
However, Anthony Scaramucci, CEO of investment firm&nbsp;SkyBridge Capital, has backed the strategy, arguing that the narrative that Bitcoin drops will force the company to liquidate its stash is overblown.
Price Action: At the time of writing, Bitcoin was exchanging hands at $93,573.37, down 0.90% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard" target="_blank" rel="noreferrer noopener">data from Benzinga Pro</a>.
Shares of MicroStrategy closed 1.14% higher at $327.91 during Friday&#8217;s regular session. The stock has a consensus price target of $449.5 based on ratings by 12 analysts, with an average price target of $546.67 from Bernstein, TD Cowen, and Barclays.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/01/42935597/mark-cuban-advocates-bitcoin-over-gold-during-economic-turmoil-i-think-it-has-more-value-than-gold">Mark Cuban Advocates Bitcoin Over Gold During Economic Turmoil: &#8216;I Think It Has More Value Than Gold&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

$BTC

MSTR

Michael Saylor's MicroStrategy Will Struggle When Bitcoin's Volatility Falls, Says Arthur Hayes — I Would Not Trade MSTR At All

Johnson & Johnson: Tracking Well Above The Industry

Alvotech GAAP EPS of -$0.63, revenue of $339M

Alvotech (ALVO) has released an update. Alvotech has reported a significant financial turnaround for the first nine months of 2024, with total reve...

Alvotech Showcases Strong Financial Growth and Expansion

Alvotech (ALVO) Q3 2024 Earnings Call Transcript

Alvotech ( ($ALVO) ) has released its Q3 earnings. Here is a breakdown of the information Alvotech presented to its investors. Alvotech is a global...

Alvotech Reports Strong Revenue Growth in 2024

In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Alvotech (ALVO – Research Report), with a price target...

Northland Securities Reaffirms Their Buy Rating on Alvotech (ALVO)

Alvotech's Position In The Coming Biosimilar Gold Rush

Northland Securities analyst Carl Byrnes maintained a Buy rating on Alvotech (ALVO – Research Report) today and set a price target of $28.00. The c...

Northland Securities Keeps Their Buy Rating on Alvotech (ALVO)

FDA approves Celltrion's biosimilar of J&J's Stelara

Alvotech ( ($ALVO) ) just unveiled an announcement. Alvotech announced its inclusion in the Nasdaq Biotechnology Index, effective December 23, 2024...

Alvotech Joins Nasdaq Biotechnology Index, Boosting Industry Presence

ABBV

ALVO

ALVOW

AMGN

AZNCF

BEIGF

BGNE

BMYMP

LEGN

NVSEF

TEVA

Press Releases

Alvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

Alvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®

Health Care

Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)

Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19–20, 2024

Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET

Comments

Alvotech

Alvotech (ALVO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO